Ultrasensitive ctDNA detection improves risk prediction in early-stage lung cancer

Ultrasensitive ctDNA detection with NeXT Personal shows 81% sensitivity in early-stage lung adenocarcinoma, improving prognostic accuracy and therapy guidance.